Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Moves On NDA For First US OTC Birth Control, Scheduling Joint Ad Comm Meeting

Sep 16 2022

• By Lauren Nardella

Related Content

Age-Restriction Labeling, Behind-The-Counter Sales Likely In HRA's US OTC Contraceptive NDA

Aug 25 2022

US OTC Birth Control NDA Could Debut ‘Additional Conditions for Nonprescription Use’ Labeling

Aug 23 2022

Perrigo Starts Supply Chain Overhaul After Filing OTC Birth Control NDA, Launching Nasonex Switch

Aug 09 2022

Perrigo’s First National Brand, Nasonex OTC Switch, Will Have Familiar Buzz In Advertising

Mar 21 2022

US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application

Jul 12 2022

Podcast Special: The Shifting Landscape For Drugs And Devices Post-Roe v. Wade

Jul 19 2022

Additional Topics

United States FDA Advisory Committees OTC Drugs Regulation Consumer

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window